MULTIVIR INC has a total of 30 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets biotechnology, pharmaceuticals and environmental technology are INNAVIRVAX, NOVOPHARM BIOTECH INC and ADVAXIS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 5 | |
#2 | United States | 5 | |
#3 | Australia | 4 | |
#4 | China | 4 | |
#5 | WIPO (World Intellectual Property Organization) | 4 | |
#6 | Canada | 3 | |
#7 | Republic of Korea | 3 | |
#8 | Hungary | 1 | |
#9 | Mexico | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Environmental technology | |
#4 | Measurement | |
#5 | Telecommunications | |
#6 | IT methods for management |
# | Name | Total Patents |
---|---|---|
#1 | Sobol Robert E | 25 |
#2 | Chada Sunil | 22 |
#3 | Menander Kerstin B | 18 |
#4 | Wiederhold Dora | 15 |
#5 | Menander Kerstin | 11 |
#6 | Sobol Robert | 4 |
#7 | Robert E Sobol | 1 |
#8 | Kerstin Menander | 1 |
Publication | Filing date | Title |
---|---|---|
US2021090124A1 | P53 biomarkers | |
KR20200135986A | Methods and compositions for cancer treatment comprising tumor suppressor gene therapy and CD122/CD132 agonists | |
WO2019183117A1 | Methods and compositions comprising genetically engineered vaccines for the treatment and prevention of cancer | |
CA3046961A1 | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases | |
CN108884159A | The composition use for cancer treatment blocked comprising tumor suppressor gene treatment and immunologic test point | |
CN106841616A | P53 biomarkers |